Gabapentin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Overview== | ==Overview== | ||
==Dosing and Administration== | ==Dosing and Administration== | ||
Gabapentin is given orally with or without food. Half-tablets not used within several days of breaking the scored tablet should be discarded. | Gabapentin is given orally with or without food. Half-tablets not used within several days of breaking the scored tablet should be discarded. | ||
| Line 187: | Line 152: | ||
<br> | <br> | ||
<br> | <br> | ||
==Category== | |||
==FDA Package Insert== | |||
==NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution Normal 0 false false false EN-US X-NONE X-NONE == | |||
''' [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution indications and usage|Indications and Usage]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution dosage and administration|Dosage and Administration]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution contraindications|Contraindications]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution adverse reactions|Adverse Reactions]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution drug interactions|Drug Interactions]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution use in specific populations|Use in Specific Populations]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution overdosage|Overdosage]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution description|Description]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution clinical studies|Clinical Studies]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution patient counseling information|Patient Counseling Information]]''' | |||
'''| [[NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
==References== | |||
{{Reflist|2}} | |||
{{Antimigraine preparations}} | |||
[[Category:Drugs]] | |||
==Patient Resources== | ==Patient Resources== | ||
Revision as of 22:53, 12 February 2014
| Gabapentin |
|---|
| NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Gabapentin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information about Gabapentin, click here.
Synonyms / Brand Names: ®,
Overview
Dosing and Administration
Gabapentin is given orally with or without food. Half-tablets not used within several days of breaking the scored tablet should be discarded.
Postherpetic Neuralgia: a single 300-mg dose on Day 1, 600 mg/day on Day 2 (divided BID), and 900 mg/day on Day 3 (divided TID). The dose can subsequently be titrated up as needed for pain relief to a daily dose of 1800 mg (divided TID).
Epilepsy: For age 12+, 900 to 1800 mg/day in divided dosage, starting at 300mg TID. For ages 3-12, 10–15 mg/kg/day in 3 divided doses, and the effective dose reached by increasing over 3 days. (effective dose for age 5+:25–35 mg/kg/day divided TID; age 3-4: 40 mg/kg/day divided TID)
Dosage in the elderly:Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients.
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Gabapentin
Return to top
Publication Resources
Most Recent Articles on Gabapentin
Review Articles on Gabapentin
Articles on Gabapentin in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Gabapentin
Return to top
Trial Resources
Ongoing Trials with Gabapentin at Clinical Trials.gov
Trial Results with Gabapentin
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Gabapentin
Cochrane Collaboration on Gabapentin
Cost Effectiveness of Gabapentin
Return to top
Media Resources
Powerpoint Slides on Gabapentin
Images of Gabapentin
Podcasts & MP3s on Gabapentin
Videos on Gabapentin
Return to top
Category
FDA Package Insert
NEURONTIN (gabapentin) capsule , NEURONTIN (gabapentin) tablet, film coated , NEURONTIN (gabapentin) solution Normal 0 false false false EN-US X-NONE X-NONE
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
Template:Antimigraine preparations
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Gabapentin
Discussion Groups on Gabapentin
Patient Handouts on Gabapentin
Blogs on Gabapentin
Gabapentin in the News
Gabapentin in the Marketplace
Return to top
International Resources
Gabapentin en Español
Return to top
Adapted from the FDA Package Insert.